Department of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Oncotarget. 2024 Aug 2;15:535-540. doi: 10.18632/oncotarget.28617.
WNT signaling regulates osteosarcoma proliferation. However, there is controversy in the field of osteosarcoma as to whether WNT signaling is pro- or anti-tumorigenic. WNT-targeting therapeutics, both activators and inhibitors, are compared. WNT5B, a β-catenin-independent ligand, and WNT10B, a β-catenin-dependent WNT ligand, are each expressed in osteosarcomas, but they are not expressed in the same tumors. Furthermore, WNT10B and WNT5B regulate different histological subtypes of osteosarcomas. Using WNT signaling modulators as therapeutics may depend on the WNT ligand and/or the activated signaling pathway.
WNT 信号通路调控骨肉瘤的增殖。然而，在骨肉瘤领域，WNT 信号通路到底是促进还是抑制肿瘤发生存在争议。目前比较了 WNT 靶向治疗的激活剂和抑制剂。WNT5B 是一种不依赖于β-catenin 的配体，WNT10B 是一种依赖于β-catenin 的 WNT 配体，两者均在骨肉瘤中表达，但并非在同一肿瘤中表达。此外，WNT10B 和 WNT5B 调控不同组织学亚型的骨肉瘤。WNT 信号通路调节剂作为治疗药物的应用可能取决于 WNT 配体和/或激活的信号通路。
